NCT01942915

Umbilical Cord Blood Mononuclear Cells Therapy in Liver Cirrhosis

Safety and Efficacy Investigation of Patients With Liver Cirrhosis by Transplantation of Umbilical Cord Blood Mononuclear Cells

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Hebei Medical University · Academic / Other
• Sex: All
• Age: 20 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study is to evaluate the safety and efficacy of umbilical cord blood mononuclear cells transplantation in liver cirrhosis patients.

Detailed description

Decompensated liver cirrhosis (LC), a life-threatening complication of chronic liver disease, is one of the major indications for liver transplantation. Recently, umbilical cord blood mononuclear cells transfusion has been shown to lead to the regression of liver fibrosis in animal model. The investigators thus investigated the safety of the therapy with life signs like temperature, pulse, blood pressure, the incidence of hepatocellular carcinoma and mortality and so on. And the efficacy was evaluated with the measurement of alanine aminotransferase (ALT), glutamic oxaloacetic transaminase (AST), total bilirubin (TBIL), direct bilirubin (DBIL), albumin (ALB), cholinesterase (CHE), prothrombin time (PT) and child-pugh score.

Conditions

• Liver Cirrhosis

Interventions

Type	Name	Description
BIOLOGICAL	Umbilical Cord Blood Mononuclear Cells	Participants will be transplanted with umbilical cord blood mononuclear cells.

Timeline

• Start date: 2012-01-01
• Primary completion: 2013-12-01
• Completion: 2014-12-01
• First posted: 2013-09-16
• Last updated: 2013-11-15

Locations

1 site across 1 country: China